Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

591P - A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Prostate Cancer

Presenters

Rahul Aggarwal

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

R.R. Aggarwal1, J. Vuky2, D. VanderWeele3, M. Rettig4, E. Heath5, M. Nasoff6, A. Dorr6, B. Liu7, E.J. Small8

Author affiliations

  • 1 Hematology/oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 94143 - San Francisco/US
  • 2 Medical Oncology, OHSU Knight Cancer Institute, 97239-4503 - Portland/US
  • 3 Hematology/oncology, Robert H. Lurie Comprehensive Cancer Center at Northwestern University, 60611 - Chicago/US
  • 4 Medicine And Urology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles, 90026-1118 - Los Angeles/US
  • 5 Oncology, Karmanos Cancer Institute, 48201 - Detroit/US
  • 6 -, Fortis Therapeutics, Inc., 92037 - La Jolla/US
  • 7 Anesthesia, UCSF School of Medicine, 94110 - San Francisco/US
  • 8 Medicine And Urology, UCSF Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 591P

Background

Cluster of differentiation 46 (CD46) is expressed at high level in CRPC and expression is further enriched upon androgen signaling inhibition (ASI) and in treatment-emergent small cell neuroendorcine prostate cancer (t-SCNC). FOR46 is a vc-MMAE antibody-drug conjugate that recognizes a tumor selective epitope of CD46. FOR46 binds to CD46 with high affinity and demonstrates anti-tumor activity in prostate cancer xenografts. A first-in-human study of safety and preliminary efficacy of FOR46 in mCRPC patients (pts) was undertaken.

Methods

Pts with mCRPC, including pts with tSCNC, following progression on at least one prior ASI were enrolled. No prior chemotherapy for mCRPC was allowed. An accelerated titration followed by 3+3 dose escalation design was used. Following excess toxicity (neutropenia and fatigue) in pts with high body mass index (BMO), dosing was changed from actual body weight to adjusted body weight. G-CSF secondary propylaxis was specified for pts experiencing grade (gr) ≥ 3 neutropenia during a previous treatment cycle.

Results

Thrity-three pts were enrolled at 10 dose levels from 0.1 to 3.0 mg/kg. Median age was 66 (range 42-81); median baseline PSA was 41 (range 0.2 - 1627); 7 pts had visceral organ metastases. Dose limiting toxicities were gr 4 neutropenia in 3 of 3 high BMI pts at 2.4 mg/kg dosed by actual body weight and 2 of 3 pts at 3.0 mg/kg dosed by adjusted body weight. The MTD was 2.7 mg/kg by adjusted body weight. The most common related adverse events were gr 4 neutropenia in 11 of 33 pts (33%), gr 3 neutropenia in 6 (18%) and infusion related reactions (IRR) in 14 (42%) with 1 gr 3 IRR. Any gr neuropathy occurred in 7 pts (21%), with 1 gr 3 neuropathy (3%). At 1.2 mg/kg or higher (n = 24), 9 pts (38%) had a PSA50 responnse and 15 (63%) had any decline in PSA. Of 8 pts with measurable disease, 1 partial response was reported and 6 had stable disease lasting from 9 to 39 weeks. The median number of treatment cycles is 6 (range 1-23) with 11 ongoing.

Conclusions

FOR46 demonstrates an acceptable toxicity profile using adjusted body weight dosing, and encouraging preliminary evidence of efficacy in ASI-resistant mCRPC pts. FOR46 is currently being evaluated in 2 mCRPC expansion cohorts: adenocarcinoma and t-SCNC.

Clinical trial identification

NCT03575819.

Editorial acknowledgement

Legal entity responsible for the study

Fortis Therapeutics, Inc.

Funding

Fortis Therapeutics, Inc.

Disclosure

R.R. Aggarwal: Non-Financial Interests, Institutional, Principal Investigator: Fortis Therapeutics. J. Vuky: Non-Financial Interests, Institutional, Principal Investigator: Fortis Therapeutics; Financial Interests, Personal, Advisory Role: Astellas; Non-Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Advisory Role: Seattle Genetics; Non-Financial Interests, Institutional, Principal Investigator: Novartis; Non-Financial Interests, Institutional, Principal Investigator: Roche/Genentech; Non-Financial Interests, Institutional, Principal Investigator: Innocrin Pharma; Non-Financial Interests, Institutional, Principal Investigator: Celldex; Non-Financial Interests, Institutional, Principal Investigator: Arvinas. D. VanderWeele: Financial Interests, Personal, Advisory Role: Clovis Oncology; Financial Interests, Personal, Advisory Role: Genentech; Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Institutional, Principal Investigator: Fortis Therapeutics, Inc. M. Rettig: Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Ambrx; Financial Interests, Personal, Advisory Role: Roivant; Financial Interests, Institutional, Research Grant: Johnson & Johnson; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Johnson & Johnson; Non-Financial Interests, Institutional, Principal Investigator: Fortis Therapeutics, Inc. E. Heath: Non-Financial Interests, Institutional, Principal Investigator: Fortis Therapeutics; Other, Personal, Advisory Role: Astellas; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Bayer; Other, Personal, Other: Caris Life Science; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Advisory Board: Seattle Genetics. M. Nasoff: Financial Interests, Personal, Officer: Fortis Therapeutics. A. Dorr: Financial Interests, Personal, Officer: Fortis Therapeutics; Financial Interests, Personal, Officer: BrightPath BioTherapeutics; Financial Interests, Personal, Officer: Curegenix; Financial Interests, Personal, Officer: Cend Therapeutics; Financial Interests, Personal, Officer: Phoenix Molecular Designs; Financial Interests, Personal, Advisory Role: Virtuoso BINCO; Financial Interests, Personal, Officer: Vivace Therapeutics. B. Liu: Financial Interests, Personal, Member of the Board of Directors: Fortis Therapeutics, Inc; Financial Interests, Personal, Stocks/Shares: Vivace Therapeutics; Financial Interests, Personal, Advisory Role: Merck Sharpe and Dohme. E.J. Small: Financial Interests, Personal, Advisory Role: Fortis Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.